Equities analysts forecast that Nektar Therapeutics (NASDAQ:NKTR) will announce $26.00 million in sales for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have issued estimates for Nektar Therapeutics’ earnings, with the lowest sales estimate coming in at $23.60 million and the highest estimate coming in at $28.50 million. Nektar Therapeutics posted sales of $39.83 million during the same quarter last year, which would indicate a negative year over year growth rate of 34.7%. The business is expected to report its next earnings report on Thursday, February 27th.

On average, analysts expect that Nektar Therapeutics will report full year sales of $106.99 million for the current financial year, with estimates ranging from $104.40 million to $110.00 million. For the next year, analysts forecast that the business will post sales of $154.89 million, with estimates ranging from $100.89 million to $205.71 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Nektar Therapeutics.

Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.17. The business had revenue of $29.22 million for the quarter, compared to the consensus estimate of $26.42 million. Nektar Therapeutics had a negative net margin of 352.83% and a negative return on equity of 26.60%. Nektar Therapeutics’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period last year, the firm posted ($0.56) earnings per share.

A number of equities research analysts recently weighed in on NKTR shares. Cowen reaffirmed a “buy” rating on shares of Nektar Therapeutics in a research note on Thursday, November 7th. Mizuho initiated coverage on shares of Nektar Therapeutics in a research note on Friday, January 10th. They issued a “hold” rating and a $21.00 target price on the stock. Zacks Investment Research raised shares of Nektar Therapeutics from a “hold” rating to a “strong-buy” rating and set a $30.00 price target on the stock in a research note on Monday. HC Wainwright reissued a “hold” rating and set a $32.00 price target on shares of Nektar Therapeutics in a research note on Friday, January 10th. Finally, BidaskClub downgraded shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 30th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $30.43.

In other news, CFO Gil M. Labrucherie sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $19.79, for a total value of $494,750.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Jonathan Zalevsky sold 3,960 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $17.97, for a total transaction of $71,161.20. Following the completion of the transaction, the insider now owns 291,697 shares in the company, valued at approximately $5,241,795.09. The disclosure for this sale can be found here. Insiders have sold 54,092 shares of company stock worth $1,017,533 over the last three months. Insiders own 4.02% of the company’s stock.

Several institutional investors have recently modified their holdings of NKTR. Invesco Ltd. grew its holdings in shares of Nektar Therapeutics by 1,057.7% in the second quarter. Invesco Ltd. now owns 23,343,019 shares of the biopharmaceutical company’s stock worth $830,544,000 after purchasing an additional 21,326,731 shares during the last quarter. Great Point Partners LLC bought a new position in shares of Nektar Therapeutics in the third quarter worth approximately $38,707,000. Millennium Management LLC bought a new position in shares of Nektar Therapeutics in the third quarter worth approximately $18,034,000. Nuveen Asset Management LLC bought a new position in shares of Nektar Therapeutics in the second quarter worth approximately $33,330,000. Finally, BlackRock Inc. grew its holdings in shares of Nektar Therapeutics by 6.0% in the second quarter. BlackRock Inc. now owns 13,264,987 shares of the biopharmaceutical company’s stock worth $471,969,000 after purchasing an additional 749,644 shares during the last quarter. Hedge funds and other institutional investors own 99.77% of the company’s stock.

NKTR traded down $1.42 on Friday, reaching $22.48. The company had a trading volume of 3,476,639 shares, compared to its average volume of 4,283,517. The business has a 50 day simple moving average of $21.90 and a 200 day simple moving average of $22.09. The company has a market cap of $4.20 billion, a price-to-earnings ratio of 5.95 and a beta of 2.60. The company has a debt-to-equity ratio of 0.26, a quick ratio of 12.49 and a current ratio of 12.60. Nektar Therapeutics has a 52-week low of $15.64 and a 52-week high of $47.11.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.

Further Reading: What is the outlook for the FAANG stocks?

Get a free copy of the Zacks research report on Nektar Therapeutics (NKTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.